Log in | Register

Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension

André P. Lourenço| Francisco Vasques-Nóvoa| José Oliveira-Pinto| Dulce Fontoura| Roberto Roncon-Albuquerque Jr.| Adelino F. Leite-Moreira
Experimental
Volume 38, Issue 6 / June , 2012

Pages 1050 - 1060

Abstract

Purpose

Chronic pulmonary hypertension (PH) therapy is poorly investigated in intensive care. Our aim was to evaluate haemodynamic and neuroendocrine effects of the dual endothelin-1 (ET-1) blocker tezosentan in monocrotaline (MCT)-induced PH.

Methods

Male Wistar rats (180–200 g, n = 194) randomly received 60 mg kg−1 MCT or vehicle, subcutaneously, and 2 days later, a subgroup of MCT-injected rats was gavaged with 300 mg kg−1 day−1 bosentan (MCT BOS, n = 46), while another (MCT, n = 125) and control rats (Ctrl, n = 23) received vehicle. At 25–30 days, 48 h after interrupting bosentan, rats randomly underwent either a dose–response evaluation (0.5–20 mg kg−1, n = 7 each group) or a 4 h perfusion of tezosentan (20 mg kg−1 in 10 min + 10 mg g−1 h−1) or vehicle (n = 8 per group, each). Haemodynamics, including blood gas analysis, were evaluated after thoracotomy under anaesthesia. After plasma, right ventricle (RV) and lung collection, plasma ET-1, cytokines, nitrate and 6-keto-PGF1α, and lung and right ventricular gene expression and cyclooxygenase (COX) and nitric oxide synthase (NOS) activities were quantified.

Results

Monocrotaline resulted in PH, RV dilation and decreased cardiac output (CO) that were attenuated in MCT BOS. Pulmonary hypertension was attenuated by tezosentan without systemic hypotension. Tezosentan increased CO without changing ventilation-perfusion matching. Both bosentan and tezosentan reduced ET-1 and cytokine plasma levels and tissue expression, and inducible NOS and COX-2 RV activities. Bosentan increased nitrate plasma levels and non inducible NOS activities whereas tezosentan decreased circulating 6-keto-PGF1α but increased lung COX-1 activity.

Conclusions

Tezosentan may be useful for haemodynamic handling and bosentan replacement in critically ill PH patients exerting important beneficial neuroendocrine and anti-inflammatory actions.

Keywords

References

  1. Lourenco AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF (2011) Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol. doi:10.1016/j.ijcard.2011.05.066
  2. Humbert M (2009) Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 179:650–656
    • View reference on PubMed
    • View reference on publisher's website
  3. Kerbaul F, Rondelet B, Collart F, Naeije R, Gouin F (2005) [Pulmonary arterial hypertension in intensive care unit and operating room]. Ann Fr Anesth Reanim 24:528-540. Epub 2005 Apr 2012
  4. McLaughin VV, Hoeper MM (2005) Pulmonary arterial hypertension: the race for the most effective treatment. Am J Respir Crit Care Med 171:1199–1201
    • View reference on PubMed
    • View reference on publisher's website
  5. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Löffler BM, Coassolo P, Roux S (1999) Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290:840–847
    • View reference on PubMed
  6. Zamanian RT, Haddad F, Doyle RL, Weinacker AB (2007) Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 35:2037–2050
    • View reference on PubMed
    • View reference on publisher's website
  7. Rex S, Missant C, Segers P, Rossaint R, Wouters PF (2008) Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility. Intensive Care Med 34:179–189
  8. Cornet AD, Hofstra JJ, Swart EL, Girbes AR, Juffermans NP (2010) Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med 36:758–764
  9. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF (2006) Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111:508–531. Epub 2006 Feb 2002.
  10. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM (2000) Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 101:142–147
    • View reference on PubMed
  11. Kuklin V, Kirov MY, Evgenov OV, Sovershaev MA, Sjöberg J, Kirova SS, Bjertnaes LJ (2004) Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep. Crit Care Med 32:766–773
    • View reference on PubMed
    • View reference on publisher's website
  12. Tsang J, Lamm WJ, Neradilek B, Polissar NL, Hlastala MP (2007) Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism. J Appl Physiol 102:762–771
    • View reference on PubMed
    • View reference on publisher's website
  13. Geiger R, Kleinsasser A, Meier S, Neu N, Pajk W, Fischer V, Treml B, Stein JI, Loeckinger A (2008) Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Med 34:368–376
  14. Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E (2004) Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. Crit Care Med 32:1192–1199
    • View reference on PubMed
    • View reference on publisher's website
  15. Fitzgerald RK, Oishi P, Ovadia B, Ross GA, Reinhartz O, Johengen MJ, Fineman JR (2004) Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension. Pediatr Crit Care Med 5:571–577
    • View reference on PubMed
    • View reference on publisher's website
  16. Lourenco AP, Roncon-Albuquerque R, Jr., Bras-Silva C, Faria B, Wieland J, Henriques-Coelho T, Correia-Pinto J, Leite-Moreira AF (2006) Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 291:H1587–1594. Epub 2006 May 1585
  17. Gan CT, Lankhaar JW, Marcus JT, Westerhof N, Marques KM, Bronzwaer JG, Boonstra A, Postmus PE, Vonk-Noordegraaf A (2006) Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 290:H1528–1533
    • View reference on PubMed
  18. Lai YL, Thacker AA, Diana JN (1996) Hypoxemia and elevated tachykinins in rat monocrotaline pneumotoxicity. Lung 174:195–203
    • View reference on PubMed
  19. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z (2009) Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54:668–675
    • View reference on PubMed
    • View reference on publisher's website
  20. Crosswhite P, Sun Z (2010) Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 28:201–212
    • View reference on PubMed
    • View reference on publisher's website
  21. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O (2003) Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 60:692–699
    • View reference on PubMed
    • View reference on publisher's website
  22. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Sakata Y, Shimada K, Ozawa K (2007) Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension 50:531–536
    • View reference on PubMed
    • View reference on publisher's website
  23. Santilli F, Davi G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Paloscia L, Minuz P, Meneguzzi A, Ciabattoni G, Patrono C (2010) Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost 8:914–922
    • View reference on PubMed
    • View reference on publisher's website
  24. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70–75
    • View reference on PubMed
    • View reference on publisher's website
  25. Fike CD, Kaplowitz MR, Pfister SL (2003) Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am J Physiol Lung Cell Mol Physiol 284:L316–323
    • View reference on PubMed
  26. Elahi M, Asopa S, Matata B (2007) NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure. Biochim Biophys Acta 1772:5–14
    • View reference on PubMed
  27. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, Mayer K, Bohle RM, Seeger W, Grimminger F, Sibelius U (2000) Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 102:2758–2764
    • View reference on PubMed
  28. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A (1998) Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98:100–103
    • View reference on PubMed
  29. Shi CZ, Zhang XP, Lv ZW, Zhang HL, Xu JZ, Yin ZF, Yan YQ, Wang CQ (2012) Adipose tissue-derived stem cells embedded with eNOS restore cardiac function in acute myocardial infarction model. Int J Cardiol 154:2–8
    • View reference on PubMed
    • View reference on publisher's website
  30. Miller JD, Peotta VA, Chu Y, Weiss RM, Zimmerman K, Brooks RM, Heistad DD (2010) MnSOD protects against COX1-mediated endothelial dysfunction in chronic heart failure. Am J Physiol Heart Circ Physiol 298:H1600–1607
    • View reference on PubMed
    • View reference on publisher's website
  31. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM, Naeije R (2003) Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107:1329–1335
    • View reference on PubMed
    • View reference on publisher's website
  32. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C (2006) Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231:967–973
  33. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT (2005) Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 172:352–357
    • View reference on PubMed
    • View reference on publisher's website
  34. Clozel M, Qiu C, Qiu CS, Hess P, Clozel JP (2002) Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39:142–147
    • View reference on PubMed
    • View reference on publisher's website
  35. Aravindan N, Cata JP, Dougherty PM, Shaw AD (2006) Effect of fenoldopam on ischemia/reperfusion-induced apoptosis. Ren Fail 28:337–344
    • View reference on PubMed
    • View reference on publisher's website
  36. Gamze K, Mehmet HM, Deveci F, Turgut T, Ilhan F, Ozercan I (2007) Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema. Exp Mol Med 39:614–620
    • View reference on PubMed
  37. Woods M, Wood EG, Bardswell SC, Bishop-Bailey D, Barker S, Wort SJ, Mitchell JA, Warner TD (2003) Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol 64:923–931
    • View reference on PubMed
    • View reference on publisher's website
  38. Spinella F, Rosano L, Di Castro V, Nicotra MR, Natali PG, Bagnato A (2004) Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res 10:4670–4679
    • View reference on PubMed
    • View reference on publisher's website
  39. Hendrickson RJ, Cappadona C, Yankah EN, Sitzmann JV, Cahill PA, Redmond EM (1999) Sustained pulsatile flow regulates endothelial nitric oxide synthase and cyclooxygenase expression in co-cultured vascular endothelial and smooth muscle cells. J Mol Cell Cardiol 31:619–629
    • View reference on PubMed
    • View reference on publisher's website
  40. Revermann M, Schloss M, Mieth A, Babelova A, Schroder K, Neofitidou S, Buerkl J, Kirschning T, Schermuly RT, Hofstetter C, Brandes RP (2011) Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med 37:1368–1377

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement